1. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, Altman R, Brandt K, Dougados M, Lequesne M: Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol. 1997, 24: 799-802.
2. Bellamy N: Osteoarthritis clinical trials: candidate variables and clinimetric properties. J Rheumatol. 1997, 24: 768-778.
3. Dougados M, LeClaire P, van der Heijde D, Bloch DA, Bellamy N, Altman RD: A report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative. Osteoarthritis Cartilage. 2000, 8: 395-403. 10.1053/joca.2000.0361.
4. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW: Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988, 15: 1833-1840.
5. Bellamy N: An evaluative index for clinical trials. Design, Measurement, and Evaluation. 1982, Hamilton, McMaster University